If you or a loved one took Oxbryta (voxelotor) to treat sickle cell disease and suffered severe side effects such as vaso-occlusive crises (VOCs), stroke, organ damage, or death, you may be entitled to compensation.
Fob James Law Firm is investigating claims against Pfizer and its subsidiary, Global Blood Therapeutics, for failing to warn patients and healthcare providers about the serious risks associated with Oxbryta.
Contact an Oxbryta injury lawyer in Memphis today for a free, no-obligation consultation to explore your legal options.
Why Choose Fob James Law Firm for Your Oxbryta Lawsuit?
When you’re facing injuries linked to Oxbryta (voxelotor), you need more than a lawyer — you need a team that understands the medical science behind your case. At Fob James Law Firm, we combine aggressive pharmaceutical litigation with expert medical analysis to build the strongest claim possible.
At Fob James Law Firm, our Oxbryta cases include
- Personalized Attention: We treat every client like family, not a file number
- Expert review by board-certified oncologists, hematologists, and pharmacology specialists
- Detailed analysis of serious complications such as vaso-occlusive crises, organ injury, blood abnormalities and adverse reactions
- Attorneys with real courtroom experience: we understand the courts, judges, and procedures that affect your claim
- Backed by national mass-tort resources – we represent over 1000 clients in 48 states
- No fees unless we win: You owe nothing out of pocket unless we recover compensation for you
If you want a law firm that understands Oxbryta science, Oxbryta injuries, and Oxbryta litigation, Fob James Law Firm is the team you want in your corner.
Why Was Oxbryta Removed from the Market?
Oxbryta, approved by the FDA in 2019 through an accelerated approval process, was marketed as a breakthrough treatment for sickle cell disease (SCD).
Designed to improve hemoglobin’s ability to carry oxygen and reduce red blood cell sickling, Oxbryta offered hope to millions living with this genetic blood disorder.
However, in September 2024, Pfizer announced a global recall of Oxbryta after clinical data revealed an increased risk of severe complications, including vaso-occlusive crises, strokes, organ failure, and fatalities.
The FDA and European Medicines Agency (EMA) have since issued warnings, citing a significant imbalance in adverse events compared to placebo groups.
Health Risks Associated With Oxbryta
Oxbryta was intended to reduce the complications of sickle cell disease, but recent studies have linked it to serious and life-threatening side effects, including:
- Vaso-Occlusive Crises (VOCs): Blockages in blood vessels causing severe pain, often requiring hospitalization.
- Stroke: Increased risk of cerebrovascular events due to impaired blood flow.
- Organ Damage: Including kidney failure, liver damage, and other long-term complications.
- Fatalities: Higher mortality rates in Oxbryta users compared to placebo groups in clinical trials.
- Other Complications: Such as increased need for blood transfusions, vision loss, and chronic pain.
These risks were not adequately disclosed to patients or healthcare providers, leading to lawsuits alleging negligence, failure to warn, and defective drug design.
Who Qualifies for the Oxbryta Lawsuit in Memphis?
You may be eligible to file an Oxbryta lawsuit if you or a loved one:
- Were prescribed and took Oxbryta for sickle cell disease.
- Experienced severe side effects such as vaso-occlusive crises, stroke, organ damage, or other serious complications.
- Suffered the loss of a loved one due to Oxbryta-related complications.
Time is critical due to statutes of limitations, which vary by state. Contact our Memphis Oxbryta injury lawyers today to determine your eligibility and protect your legal rights.
Types of Compensation Available from an Oxbryta Lawsuit
Victims of Oxbryta-related injuries may be entitled to compensation for:
- Medical Expenses: Costs for hospital stays, treatments, and ongoing care related to Oxbryta complications.
- Lost Wages: Income lost due to inability to work caused by health issues.
- Pain and Suffering: Compensation for physical pain and emotional distress.
- Wrongful Death: Damages for families who lost a loved one due to Oxbryta-related complications.
- Punitive Damages: In cases where Pfizer’s conduct is found to be egregious, additional damages may be awarded to penalize the manufacturer.
If you have questions about compensation you may be entitled to recover from a lawsuit, call a Memphis Oxbryta attorney for a free consultation
Why Choose Our Memphis Oxbryta Injury Attorneys?
At Fob James Law Firm, we are committed to holding pharmaceutical giants like Pfizer accountable for the harm caused by dangerous drugs.
Our experienced mass tort attorneys have a proven track record of securing substantial settlements and verdicts for clients nationwide.
We offer:
- Decades of Experience: Over 40 years of combined experience fighting for victims of defective drugs and medical devices.
- No Upfront Costs: We work on a contingency-fee basis, meaning you pay nothing unless we win your case.
- Personalized Attention: Our team provides compassionate, one-on-one support to guide you through the legal process.
- Extensive Resources: Access to medical experts, investigators, and cutting-edge technology to build a strong case.
We understand the devastating impact that Oxbryta’s side effects can have on your life and are dedicated to seeking the justice and compensation you deserve.
Oxbryta Lawsuit Updates
Last Updated: December 8, 2025
Our attorneys closely follow developments in the Oxbryta litigation and strive to provide monthly litigation updates.
If you have questions about litigation updates, call our Oxbryta lawsuit lawyers at 866-837-1010.
First Reported Settlement Reached in Federal Court (December 8, 2025)
At least one Oxbryta lawsuit has now officially reached a settlement. Earlier this month, the plaintiffs and defendants—Pfizer Inc. and Global Blood Therapeutics, Inc.—filed a Notice of Settlement in the U.S. District Court for the Northern District of California. As is common in pharmaceutical litigation, the settlement terms remain confidential, so no specific compensation details have been released.
The result is not public. However, this news is positive for people with Oxbryta legal claims. It is also good for those who are considering filing a lawsuit. Early settlements often signal that additional claims may also move toward resolution.
Ford v. Pfizer – Widow’s Oxbryta Lawsuit Set for Trial (November 10, 2025)
In May 2025, Diana Ford of Tennessee filed a wrongful death lawsuit against Pfizer and Global Blood Therapeutics on behalf of her late husband, Bruce Ford. According to the complaint, Mr. Ford began taking Oxbryta in 2022 to manage sickle cell disease. He reportedly suffered a stroke in April 2024 after experiencing an increase in vaso-occlusive crises (VOCs) allegedly linked to the medication.
The lawsuit claims that the manufacturers failed to adequately warn doctors and patients about the risk of severe cardiovascular events associated with Oxbryta. The case has been transferred to the U.S. District Court for the Northern District of California, where a federal judge has scheduled the trial for September 2027. We will monitor this case and post material updates as it progresses.
Early Settlement Talks and Case Value Projections (October 15, 2025)
The Oxbryta litigation remains in its early stages, but several key developments have surfaced:
- Settlement talks ongoing: Reports indicate that some federal Oxbryta cases are now in active settlement negotiation.
- New cases filed: One recent lawsuit involves parents of a child who allegedly experienced multiple vaso-occlusive crises and near-fatal complications following Oxbryta use.
- Value projections emerging: Early estimates suggest possible settlement ranges from $20,000 to over $500,000+, depending on severity of injury, though these remain speculative at this stage.
Key Next Steps in the Oxbryta Litigation (September 2, 2025)
| Date / Period | Event | What It Means for Plaintiffs |
|---|---|---|
| Sept 9, 2025 | Court-ordered mediation session with retired Judge Philip S. Gutierrez | First formal settlement discussions; may indicate Pfizer’s willingness to negotiate early payouts. |
| Late 2025 – Early 2026 | Ongoing case consolidation petitions before the Judicial Panel on Multidistrict Litigation (JPML) | If approved, an MDL will centralize cases, speeding up pre-trial discovery and creating efficiency for both sides. |
| 2026 (expected) | Discovery phase in bellwether cases | Plaintiffs’ attorneys gain access to Pfizer’s internal studies, clinical trial data, and communications; critical for proving liability. |
| Early 2027 | Expert witness testimony & Daubert hearings | Courts evaluate whether expert opinions linking Oxbryta to VOCs, organ failure, and deaths meet admissibility standards. |
| June 7, 2027 | Allen v. Pfizer bellwether trial | First major trial; outcome will influence settlement negotiations for thousands of cases. |
| Sept 13, 2027 | Ford v. Pfizer wrongful death trial | A key test case likely to impact Pfizer’s risk calculus for global settlements. |
| Late 2027 – 2028 | Potential global settlement window | If bellwether verdicts favor plaintiffs, Pfizer may move toward a broad settlement program rather than risk multiple jury trials. |
MDL Consolidation Momentum (Apr 11 – 16, 2025)
In mid-April, consolidation talks accelerated. On April 11, Judge Trina L. Thompson accepted a second federal Oxbryta complaint involving four plaintiffs, joining it with Allen v. Pfizer to streamline discovery and rulings. Days later, two new California state suits expanded the roster of defendants to multiple Sutter-affiliated hospitals, alleging defective design and failure to warn.
With eight active cases—two federal and six in state court—plaintiffs’ attorneys are preparing a petition to the U.S. Judicial Panel on Multidistrict Litigation (JPML), proposing Judge Thompson’s Northern District of California courtroom as the MDL venue. A hearing is expected in the second half of 2025.
Bellwether Trial Set for June 7, 2027 (Mar 1, 2025)
On March 1, 2025, the Northern District of California set June 7, 2027 as the opening bellwether trial date in Allen v. Pfizer. The 12–15 day trial will mark the first jury test of Oxbryta claims. Fact discovery runs through late 2026, with expert reports and Daubert motions due in early 2027.
Both sides now treat the date as a hard target: plaintiffs seek to prove Pfizer concealed internal data linking Oxbryta to increased VOCs, while the defense aims to undercut causation theories.
New Study Adds Fuel to Both Sides (Feb 3, 2025)
A small February 2025 ASH study of 60 former Oxbryta users found over half discontinued treatment within a year due to renewed vaso-occlusive pain. Those who continued saw no clear improvement in crisis frequency.
Defense lawyers cite the limited sample size and missing data to downplay the results, while plaintiffs highlight the 53% dropout rate as evidence of poor tolerability. A later American Journal of Hematology editorial underscored that Oxbryta’s recall illustrates the risks of relying on surrogate endpoints without confirming long-term outcomes.
Statute-of-Limitations Disputes (Jan 8, 2025)
At a January case-management conference, Pfizer moved to dismiss parts of early complaints, arguing California’s two-year statute of limitations bars claims predating the September 2024 recall. Plaintiffs countered with allegations of fraudulent concealment, citing internal 2022 emails that warned of elevated stroke rates.
Judge Thompson ordered separate briefing on the tolling issue, a decision that could determine whether hundreds of pre-recall claims proceed.
Wave of New Claims (Nov – Dec 2024)
Following the European Medicines Agency’s November 19, 2024 vote to revoke Oxbryta’s license, new product-liability suits were filed in California and Illinois. A December wrongful-death complaint cited internal 2023 analyses showing higher stroke rates among Oxbryta users. By year’s end, commentators agreed the recall had become “inevitable,” driven by clinical-trial dropout rates and weak efficacy data.
Filing the First Cases (Nov 1 – 9, 2024)
The first lawsuits appeared within weeks of the recall. On November 1, 2024, families in Illinois and California filed state-court actions alleging defective design and negligent marketing. A federal complaint on November 9 described a patient who began Oxbryta in August and soon suffered multiple crises and a stroke, accusing Pfizer of concealing known risks.
Europe Suspends the License (Sept 26, 2024)
A day after the FDA alert, the European Medicines Agency (EMA) suspended Oxbryta’s authorization across the EU, citing pediatric deaths and post-marketing safety data. Effective immediately, physicians were instructed to transition all patients to alternative therapies.
Global Recall Announced (Sept, 2024)
On September 25, 2024, Pfizer issued a voluntary worldwide recall after data revealed higher VOC rates and mortality among users. The next day, the FDA released a formal safety alert, advising doctors to stop prescribing the drug. All clinical trials and expanded-access programs were halted, and pharmacies were ordered to pull remaining stock.
Early Safety Warnings (Summer 2024)
Registry studies in mid-2024 showed increased vaso-occlusive crises among Oxbryta users, while the HOPE-Kids 2 trial recorded eight deaths in the treatment group versus two on placebo—findings that directly undermined the drug’s purpose.
Initial Concerns Emerge (2023 – Early 2024)
In 2023, the U.K.’s National Institute for Health and Care Excellence (NICE) declined to fund Oxbryta due to “weak clinical benefit.” A 2024 revision reaffirmed that stance, foreshad
Contact An Oxbryta Lawsuit Lawyer Near Memphis
Don’t wait to explore your legal options. If you or a loved one suffered serious complications after taking Oxbryta, contact Fob James Law Firm today for a free, confidential consultation.
Our experienced Oxbryta injury lawyers in Memphis are ready to evaluate your case, answer your questions, and fight for your rights.
Call us at 866-837-1010 or fill out our online form to get started.